Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | FLAG Therapeutics Issued Key Patent for Lead CompoundFLAG Therapeutics Announces the Issuance of a New US Patent That Includes Composition of Matter on Their Bi-Specific Lead Candidate for Oncology.
"This USPTO allowance bolsters FLAG’s robust IP portfolio and will provide a long runaway to enable us to fully develop and commercialize our lead candidate for multiple applicable cancers. We look forward to advancing our drugs to provide life-saving treatments for patients who desperately need improved therapies” said Frank Sorgi, president and chief executive officer, FLAG Therapeutics. FLAG’s bi-specific antiangiogenic and antitubulin (AA/AT) compounds are the only small-molecule compounds that combine the activities of the cornerstones of oncology therapy, anti-angiogenics and cytotoxics, without resorting to more complex and unpredictable linker, drug delivery or antibody technologies. In doing so, these FLAG’s compounds guarantee simultaneously assaults on the tumor which is critical because: · Solid tumors have a positive pressure gradient and irregular vasculature that increases the challenge of introducing cytotoxic drugs required to kill the tumor. · Anti-angiogenic drugs normalize tumor vasculature, shrink tumors and provide a transient opportunity to deliver the cytotoxic drugs necessary to kill the tumor. · If this narrow window of opportunity is missed, the route of administration for cytotoxic drugs is cut off and the remaining tumor can fragment, metastasize and develop resistance. · FLAG’s dual-acting drugs guarantee that the cytotoxic activity is delivered when the tumor pressure gradient and vasculature is normalized but before the blood supply is cut off. · Different dosing schedules, administration routes, pharmacokinetics and intra-/inter- As noted in the issued patent, FLAG’s AA/AT compounds also circumvent the two major mechanisms of drug resistance (Pgp and β-III tubulin overexpression) About FLAG Therapeutics FLAG Therapeutics is an RTP, North Carolina based company founded on breakthrough research that has yielded two novel classes of small-molecule, water-soluble oncology drugs. Their compounds have well elucidated mechanisms of action against clinically validated targets. In preclinical models, FLAG’s lead compounds have demonstrated statistically significant superiority in the appropriate disease models vs. approved comparator drugs that exceed $5 billion in sales. Each program has a late-stage preclinical lead that is one year from IND filing. To learn more about FLAG Therapeutics, please visit www.flagtherapeutics.com. Information on FLAG Therapeutics’ Contacts FLAG Therapeutics, Inc. Frank L. Sorgi, PhD President and CEO 919-294-6472 frank.sorgi@ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|